Phase 1 Lymphoma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People diagnosed with a type of blood cancer called CD20-positive B-cell non-Hodgkin lymphoma, confirmed by lab testing, who have already received two or more previous treatments for it.
- People whose physical functioning is reasonably well-maintained, rated on a standard scale as able to carry out daily activities with at most some limitations (confirm with trial site).
- People who have at least one area of lymphoma in the body that can be measured or assessed using standard imaging criteria.
- People with an expected survival of at least 3 months.
- People whose blood cell counts, kidney function, liver function, and blood clotting levels meet specific minimum thresholds as assessed by blood tests (confirm with trial site for exact values).
Who may not be able to join:
- People whose lymphoma has spread to the central nervous system (the brain and spinal cord).
- People who have previously received a bone marrow or stem cell transplant from a donor, or any other organ transplant.
- People who have previously received treatments that target a specific protein called CD47 or a related protein called SIRPα.
- People with a previous or current history of a condition where the immune system destroys red blood cells (such as hemolytic anemia or Evans syndrome), or inflammation of the blood vessels (arteritis).
- People who have or have previously had another type of cancer.
- People with a previous or current history of active autoimmune disease (conditions where the immune system attacks the body).
- People who have had major surgery within the 4 weeks before the trial starts, or who are expected to need major surgery during the trial.
- People with HIV infection, active syphilis, certain levels of active hepatitis B virus, or certain levels of active hepatitis C virus, as determined by blood tests.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Weili Zhao, Ruijin Hospital Clinical, Shanghai Jiao Tong University, School of Medicine
Phone: 86-15877976037
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Dose-limiting toxicity(DLT) and maximum tolerated dose(MTD); Incidence of treatment-emergent adverse events (TEAEs)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 15 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.